Edition:
United Kingdom

Spero Therapeutics Inc (SPRO.OQ)

SPRO.OQ on NASDAQ Stock Exchange Global Select Market

8.52USD
19 Oct 2018
Change (% chg)

-- (--)
Prev Close
$8.52
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
39,045
52-wk High
$19.00
52-wk Low
$7.89

Latest Key Developments (Source: Significant Developments)

Spero Announces Positive SPR994 Phase 1 SAD/MAD Final Results
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - Spero Therapeutics Inc ::SPERO ANNOUNCES POSITIVE SPR994 PHASE 1 SAD/MAD FINAL RESULTS.SPERO THERAPEUTICS INC - 600 MG DOSE PROVIDES GREATER DRUG EXPOSURE THAN 300 MG DOSE WITH COMPARABLE SAFETY PROFILE.SPERO THERAPEUTICS - CLINICAL DATA SUPPORTS ADVANCEMENT OF 600 MG TID DOSE FOR PIVOTAL PHASE 3 CLINICAL TRIAL, PLANNED FOR INITIATION AROUND YEAR-END.SPERO THERAPEUTICS INC - SCHEDULED A PRE-PHASE 3 MEETING WITH U.S. FOOD AND DRUG ADMINISTRATION (FDA) IN Q4 OF 2018.SPERO THERAPEUTICS INC - PLANS TO INITIATE A PIVOTAL PHASE 3 CLINICAL TRIAL OF SPR994 FOR TREATMENT OF CUTI AROUND YEAR-END 2018.SPERO THERAPEUTICS INC - ORAL ADMINISTRATION OF SPR994 WAS WELL TOLERATED AT ALL DOSES TESTED WITHIN TRIAL.  Full Article

Spero Therapeutics Q2 Loss Per Share $0.69
Thursday, 9 Aug 2018 

Spero Therapeutics Inc ::SPERO THERAPEUTICS ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND PIPELINE OVERVIEW.Q2 LOSS PER SHARE $0.69.Q2 EARNINGS PER SHARE VIEW $-0.78 -- THOMSON REUTERS I/B/E/S.CONTINUES TO EXPECT THAT ITS RESEARCH AND DEVELOPMENT EXPENSES WILL INCREASE THROUGH 2018.EXPECTS GENERAL AND ADMINISTRATIVE EXPENSES TO INCREASE THROUGH 2018.  Full Article

Spero Awarded Up To $54 Mln By BARDA, DTRA To Support SPR994 Development
Monday, 16 Jul 2018 

July 16 (Reuters) - Spero Therapeutics Inc ::SPERO AWARDED UP TO $54 MILLION BY BARDA AND DTRA TO SUPPORT SPR994 DEVELOPMENT.SPERO THERAPEUTICS INC - PLANNED PIVOTAL PHASE 3 TRIAL OF SPR994 ON TRACK TO INITIATE AROUND YEAR-END 2018.SPERO THERAPEUTICS - FUNDING TO SUPPORT FURTHER CLINICAL DEVELOPMENT OF SPERO'S ORAL CARBAPENEM PRODUCT CANDIDATE, SPR994.  Full Article

Spero Therapeutics Announces Pricing Of Securities Offering
Friday, 13 Jul 2018 

July 12 (Reuters) - Spero Therapeutics Inc ::SPERO THERAPEUTICS ANNOUNCES PRICING OF SECURITIES OFFERING.SPERO THERAPEUTICS - PRICING OF PUBLIC OFFERING OF 3.8 MILLION SHARES OF COMMON STOCK AND 2,220 SHARES OF NON-VOTING SERIES A CONVERTIBLE PREFERRED STOCK.SPERO THERAPEUTICS -PUBLIC OFFERING PRICE OF EACH SHARE OF COMMON STOCK IS $12.50.PUBLIC OFFERING PRICE OF EACH SHARE OF SERIES A PREFERRED STOCK IS $12,500.00..  Full Article

Spero Therapeutics Announces Proposed Offering Of Common Stock
Monday, 9 Jul 2018 

July 9 (Reuters) - Spero Therapeutics Inc ::SPERO THERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK.SAYS OFFERING 4.50 MILLION COMMON SHARES.  Full Article

Spero Reports Positive Interim Phase 1 SAD/MAD Results For SPR994
Monday, 9 Jul 2018 

July 9 (Reuters) - Spero Therapeutics Inc ::SPERO ANNOUNCES POSITIVE INTERIM PHASE 1 SAD/MAD RESULTS FOR SPR994.CLINICAL DATA DEMONSTRATE SPR994 TO BE WELL TOLERATED AT SINGLE AND MULTIPLE ASCENDING DOSES.EXPECTS TO REPORT FINAL DATA FROM MAD PORTION OF PHASE 1 CLINICAL TRIAL IN Q3 OF 2018.DATA SUPPORT SELECTION OF SPR994 300 MG TID DOSE FOR USE IN PIVOTAL PHASE 3 CLINICAL TRIAL, PLANNED TO INITIATE AROUND YEAR-END 2018.EXPECTS TO REQUEST A PRE-PHASE 3 MEETING WITH FDA IN SECOND HALF OF 2018.  Full Article

Spero Therapeutics Reports Q1 Loss Per Share $0.74
Thursday, 10 May 2018 

May 10 (Reuters) - Spero Therapeutics Inc ::SPERO THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PIPELINE UPDATE.Q1 LOSS PER SHARE $0.74.Q1 EARNINGS PER SHARE VIEW $-1.20 -- THOMSON REUTERS I/B/E/S.PLANS TO INITIATE A PIVOTAL PHASE 3 CLINICAL TRIAL OF SPR994 FOR TREATMENT OF CUTI AROUND YEAR-END 2018 IN SUPPORT OF A NDA.EXPECTS THAT ITS RESEARCH AND DEVELOPMENT EXPENSES WILL INCREASE THROUGH 2018.BELIEVES THAT ITS EXISTING CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WILL FUND OPERATIONS THROUGH LATE IN Q2 OF 2019.  Full Article

Spero Therapeutics Posts Qtrly Loss Of $1.59 Per Share
Monday, 2 Apr 2018 

April 2 (Reuters) - Spero Therapeutics Inc ::SPERO THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 OPERATING RESULTS AND PROVIDES PIPELINE UPDATE.QTRLY LOSS PER SHARE $1.59.EXPECTS THAT ITS RESEARCH AND DEVELOPMENT EXPENSES WILL INCREASE THROUGHOUT 2018.BELIEVES EXISTING CASH AND CASH EQUIVALENTS WILL FUND OPERATING EXPENSES & CAPITAL EXPENDITURE REQUIREMENTS INTO Q2 2019.AS OF DEC 31, 2017, CO HAD CASH AND CASH EQUIVALENTS OF $87.3 MILLION.  Full Article

Spero Therapeutics Q3 Loss Per Share $36.02
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Spero Therapeutics Inc ::SPERO THERAPEUTICS ANNOUNCES 3Q17 OPERATING RESULTS AND PIPELINE UPDATE.Q3 LOSS PER SHARE $36.02.Q3 EARNINGS PER SHARE VIEW $-2.43 -- THOMSON REUTERS I/B/E/S.  Full Article

‍GlaxoSmithKline reports 13.3 percent stake in Spero Therapeutics
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Spero Therapeutics Inc :‍GlaxoSmithKline PLC reports a 13.3 percent stake in Spero Therapeutics Inc as of November 6 - SEC filing​.  Full Article